Solving the EV Consistency Challenge
FT-01: Our platform for consistent, scalable extracellular vesicle production
Our Vision
Our vision is to lead a new era in regenerative medicine by unlocking the full potential of extracellular vesicles (EVs) and delivering life-changing therapies enabled by consistent, scalable EV production through our FT-01 platform.
What We Do
Mesenbio is advancing a new generation of EV therapeutics powered by FT-01, our proprietary, immortalised mesenchymal stem cell line. FT-01 delivers consistent, scalable EV production, solving one of the field’s biggest barriers and enabling clinical-grade manufacturing for regenerative and targeted therapies.
Our platform-first strategy focuses on establishing FT-01 as the go-to production platform for EV-based therapeutics, while validating its therapeutic potential through MEV-N01, our proof-of-concept program for rheumatoid arthritis (RA).
The EV Consistency Breakthrough
The Challenge:
Traditional EV Limitations
EVs offer transformative therapeutic potential by harnessing the body's own cellular messaging systems to deliver therapeutic signals, modulate immune responses, and drive tissue repair. Yet despite this promise, EV therapies have been held back by a fundamental limitation: consistency.
Most EVs are produced from primary donor cells, which vary from batch to batch, making them difficult to regulate or scale. This donor-dependent variability has prevented the field from realising its full clinical and commercial potential.
The Solution:
FT-01's Consistent Production
FT-01 solves this critical bottleneck. As a clonal, stable, and inexhaustible cell line, it enables the consistent manufacture of potent, bioactive EVs with the quality and reliability needed for clinical development and commercialisation.
We're using FT-01 to unlock a new generation of EV-based therapeutics, powering both our lead proof-of-concept program in RA and external innovation through strategic partnerships.
Platform Capabilities
Four Pillars of the FT-01 Advantage
Unmatched Consistency
FT-01's clonal, immortalised cell line produces EVs with consistent characteristics, eliminating the batch-to-batch variability that has limited traditional EV production.
Breakthrough Scalability
We've achieved significant reduction in cost of goods while scaling production to commercially relevant levels, demonstrating FT-01's manufacturing potential.
GMP-Ready Design
Our platform is designed for regulatory compliance and quality systems, providing partners with a turnkey solution for clinical-grade EV production.
Multimodal Therapeutic Profile
FT-01 EVs combine anti-inflammatory and regenerative properties, offering a holistic approach to treating complex diseases.
MEV-N01
Proof of Concept
From Symptomatic Relief to Tissue Repair
MEV-N01, derived from FT-01, is our proof-of-concept program demonstrating the therapeutic potential of consistent, scalable EVs in RA.
This regenerative EV therapy targets both the cause and consequence of inflammatory arthritis, combining immune modulation to reduce inflammation with activation of tissue repair pathways. Delivered via local injection directly into the joint, MEV-N01 offers a minimally invasive approach that could delay or prevent the need for joint replacement surgery.
In preclinical models, MEV-N01 has shown meaningful improvements in joint inflammation and tissue regeneration, validating FT-01's potential to support disease-modifying EV therapies.
Partnership Opportunities
Partner With Mesenbio
As a scalable, licensing-ready platform, FT-01 has the potential to become the gold standard for EV production, democratising access to consistent, GMP-grade EVs for a wide range of therapeutic applications — from regenerative medicine and immunology to oncology and CNS disorders.
Partnership Applications:
New therapeutic areas using naïve EVs from FT-01
Precision-targeted delivery with tissue-specific EV engineering
Custom therapeutic payloads including nucleic acids, proteins, or small molecules